Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

Fig. 3

Box plots (median, minimum, and maximum) of serum B-cell-activating factor (BAFF) and immunoglobulin M (IgM) levels after rituximab treatment during follow-up by late-onset neutropenia (LON) occurrence. Diagonal lined boxes represent the LON group, and open boxes represent the non-LON group. The numbers of patients with available serum for measurement of serum BAFF levels in the LON group were 11 at treatment initiation, 7 at 3 months, and 4 at 6 and 12 months; in the non-LON group, the respective numbers of patients with BAFF measurements were 48, 39, 24, and 5. The numbers of patients with measured IgM serum levels in the LON group were 11 at baseline, 10 at 6 months, and 8 at 12 months; the respective numbers of patients in the non-LON group were 47, 42, and 22

Back to article page